An observational study in Acute Heart Failure, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-07-10.
Sponsored by Sohag University · Observational
The aim of this study is to evaluate liver function test abnormalities and to identify associated cardiac and non cardiac factors mediating hepatic impairment in acute heart failure patients
Cardiac failure has a negative impact on the function of all parenchymatous organs, based both on the low organ perfusion in the left-sided failure and on the venous congestion in the right-sided failure.
The pathophysiology of acute heart failure (AHF) is complex and not fully understood. It has been hypothesized that an episode of acute decompensation affects not only the cardiovascular system itself, but may also deteriorate the function of other organs, c ausing serious clinical consequences. Liver involvement has been mostly described and investigated in patients with chronic HF.
Liver enzyme alterations are usually classified as relating predominantly to liver cell necrosis (signified by transaminase elevations) or predominantly to cholestasis (signified by elevated alkaline phosphatase (AP) level).
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients aged 18 yrs or older presenting with AHF
Exclusion Criteria:
This umbrella term includes patients presenting forthe first time with typical symptoms and signs of heart failure(de novo AHF) and also those with worsening of their pre-existing cardiomyopathy (acute decompensated heart failure).
Behavioral: Avoiding the risk factors
It's the real clinical presentation of AHF, typically, signs and symptoms develope rapidly and patients demonstrate severe respiratory distress with tachypnea, orthopnea and pulmonary congestion
Behavioral: Avoiding the risk factors
the condition is associated with elevated blood pressure with accompanying dyspnea. orthopnea and pulmonary congestion, often in patients with relatively preserved left ventricle ejection fraction
Behavioral: Avoiding the risk factors
severe peripheral hypoperfusion wih subsequent end organs damage,typically it's associated with low blood pressure and low urine output
Behavioral: Avoiding the risk factors
characterized by complex structural, hemodynamic and neurohormonal interaction need urgent referral for coronary intervention poor outcome
Behavioral: Avoiding the risk factors
Exercise, Salt and lipid reduction in diet, smoking cessation
Liver function abnormalities in patients with acute heart failure in Sohag University Hospitals
assessment the LFTs abnormalities and factors mediating hepatic impairment in patients with AHF
Time frame: baseline
Liver function abnormalities in patients with acute heart failure in Sohag University Hospitals
assessment the LFTs abnormalities and factors mediating hepatic impairment in patients with AHF
Time frame: 1 year
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University